Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 577-586, July 2010

FlipADAM: a potential new SPECT imaging agent for the serotonin transporter

  • Julie L. Wang

      Affiliations

    • Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
  • ,
  • Eric C. Deutsch

      Affiliations

    • Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
  • ,
  • Shunichi Oya

      Affiliations

    • Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
  • ,
  • Hank F. Kung

      Affiliations

    • Department of Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    • Corresponding Author InformationCorresponding author. Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA. Tel.: +1 215 662 3096; fax: +1 215 349 5035.

Received 8 December 2009; received in revised form 9 February 2010; accepted 27 February 2010. published online 09 April 2010.

Abstract 

Introduction

Single photon emission computed tomography (SPECT) imaging of the serotonin transporter (SERT) in the brain is a useful tool for examining normal physiological functions and disease states involving the serotonergic system. The goal of this study was to develop an improved SPECT radiotracer with faster kinetics than the current leading SPECT tracer, [123I]ADAM, for selective SERT imaging.

Methods

The in vitro binding affinities of (2-(2′-((dimethylamino)methyl)-4′-iodophenylthio)benzenamine) (FlipADAM) (1c), were determined using Hampshire pig kidney cells stably overexpressing the serotonin, norepinephrine (NET) or dopamine transporter (DAT). Localization of [125I]FlipADAM (1c) was evaluated through biodistribution and autoradiography in male Sprague Dawley rats, and the specificity of binding was assessed by injecting selective SERT or NET inhibitors prior to [125I]FlipADAM (1c).

Results

FlipADAM (1c) displayed a high binding affinity for SERT (Ki=1.0 nM) and good selectivity over NET and DAT binding (43-fold and 257-fold, respectively). [125I]FlipADAM (1c) successfully penetrated the blood brain barrier, as evidenced by the brain uptake at 2 min (1.75% dose/g). [125I]FlipADAM(1c) also had a good target to non-target (hypothalamus/cerebellum) ratio of 3.35 at 60 min post-injection. In autoradiography studies, [125I]FlipADAM (1c) showed selective localization in SERT-rich brain regions such as the thalamic nuclei, amygdala, dorsal raphe nuclei and other areas.

Conclusion

[125I]FlipADAM (1c) exhibited faster clearance from the brain and time to binding equilibrium when compared to [125I]2-(2′-((dimethylamino)methyl)-phenylthio)-5-iodophenylamine [125I]ADAM (1b) and a higher target to non-target ratio when compared to [125I]5-iodo-2-(2′-((dimethylamino)methyl)-phenylthio)benzyl alcohol [125I]IDAM (1a). Therefore, [123I]FlipADAM (1c) may be an improved SPECT tracer for imaging SERT.

Keywords: Brain imaging, SERT, 5-HTT, ADAM, IDAM, Autoradiography

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Financial support: This work was supported by a grant awarded from the National Institutes of Health (ROI-MH068782, H.F.K.).

PII: S0969-8051(10)00035-1

doi:10.1016/j.nucmedbio.2010.02.010

Nuclear Medicine and Biology
Volume 37, Issue 5 , Pages 577-586, July 2010